Modification of tumor cells by a low dose of Newcastle disease virus
1990; Elsevier BV; Volume: 126; Issue: 1 Linguagem: Inglês
10.1016/0008-8749(90)90302-8
ISSN1090-2163
AutoresPaul von Hoegen, Rainer Zawatzky, Volker Schirrmacher,
Tópico(s)SARS-CoV-2 and COVID-19 Research
ResumoTo investigate possibilities of augmenting tumor-specific immune responses against the highly metastatic murine lymphoma ESb, we tested the effects of the interferon inducer newcastle disease virus (NDV) or of interferon-αβ as costimulator in mixed lymphocyte-tumor cell cultures (MLTC) on the tumor-specific cytolytic T cell (CTL) response. Both approaches, namely stimulation of ESb immune spleen cells with NDV-modified stimulator cells or with ESb stimulator cells and exogenous IFN-αβ, led to a selective potentiation of tumor-specific CTL activity. The potent activation of tumor-specific CTL precursor (CTLP) required the simultaneous presence of the specific ESb tumor antigen—possibly to mediate a signal via the corresponding T cell receptor—and costimulators—possibly to mediate second activation signals. Increased CTL activity required only very low amounts of NDV or IFN-αβ. The generation of CTL activity in the MLTC cultures could be blocked by antisera to IFN-αβ, not, however by control sera. Similar effects were observed in vivo, suggesting that IFN-αβ not only caused an increase in CTL activity, but was essential for the generation of CTL activity. The reduction of the generation of CTL by antiserum to IFN-αβ could be overcome by excess interferon, especially when using ESb-NDV as stimulator Cells.
Referência(s)